Ferring Pharmaceuticals
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING4
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +23.0 months). See all sponsors →
Open Ferring Pharmaceuticals on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PICCOLO NCT04113382 |
P1/2 | Recruiting | Bowel Preparation | 39 | 2027-12 (+81 mo) |
| ABLE-22 NCT06545955 |
P3 | Recruiting | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 250 | 2028-06-30 (+23 mo) |
| ABLE-32 NCT06510374 |
P3 | Recruiting | Intermediate Risk Non-Muscle Invasive Bladder Cancer | 454 | 2028-09-30 (+2 mo) |
| LUNAR NCT06668493 |
P1/2 | Recruiting | Low-grade Upper Tract Urothelial Carcinoma | 20 | 2029-11-30 |
| FE 999326 NCT05704244 |
P3 | Active, not recruiting | Bladder Cancer | 25 | 2029-11-30 (+59 mo) |